10 Min
In Pharmacy CPD Modules
CPD modules help to expand your clinical knowledge on a whole range of topics. Make sure you log your learning so you can track your progress and add to your online revalidation record.
Bookmark
After completing this module, you will be able to:
Author: Josephine Fáladé, associate professor, UCL School of Pharmacy
Key facts
- The new NICE guidance outlines a major shift in the management of type 2 diabetes from a glucose-centred approach to one that focuses equally on glucose, cardiovascular and renal risks
- Most newly diagnosed adults should receive modified-release metformin and SGLT-2 inhibitor (e.g. dapagliflozin) as first-line therapy
- Modified-release metformin replaces standard-release metformin to increase tolerability and adherence
- SGLT-2 inhibitors can be prescribed at the same time as metformin to reduce the number of health professional appointments
- SGLT-2 inhibitors will become much more widely used – advising on side-effects and safe use will be crucial
- GLP-1 receptor agonists will be used earlier in specific groups e.g. SC semaglutide in those with atherosclerotic cardiovascular disease
- Patients with chronic kidney disease should be prescribed medicines that are tailored to their kidney function
- Patients with multiple comorbidities should be involved in decisions regarding which condition to prioritise when choosing medicines